Meningioma malignant – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Meningioma malignant – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Regorafenib for Patients with Recurrent Grade 2 and 3 Meningioma After Surgery and Radiotherapy https://clinicaltrials.eu/trial/study-on-regorafenib-for-patients-with-recurrent-grade-2-and-3-meningioma-after-surgery-and-radiotherapy/ Wed, 29 Apr 2026 14:27:27 +0000 https://clinicaltrials.eu/trial/study-on-regorafenib-for-patients-with-recurrent-grade-2-and-3-meningioma-after-surgery-and-radiotherapy/ This clinical trial is focused on studying a type of brain tumor called meningioma, specifically grades 2 and 3, which are more aggressive forms of this tumor. The study is investigating the effects of a medication called Regorafenib, also known by its code name BAY73-4506. This medication is a type of drug known as a multi-kinase inhibitor, which works by blocking certain proteins that help cancer cells grow. The purpose of the study is to see if Regorafenib can help slow down the progression of the disease in patients whose tumors have returned after surgery and radiation therapy.

Participants in the study will be randomly assigned to receive either Regorafenib or a placebo, which is a substance with no active medication. The study will take place over a period of time, during which participants will take the medication in the form of film-coated tablets. The maximum daily dose of Regorafenib is 160 milligrams, and the treatment period can last up to 18 months. Throughout the study, participants will have regular check-ups and tests, such as MRI scans, to monitor the size and growth of their tumors.

The main goal of the study is to determine if Regorafenib can extend the time patients live without their disease getting worse, known as progression-free survival. Additionally, the study will look at overall survival, which is the time from the start of the study until death from any cause, and the response of the tumor to the treatment. The study will also assess the quality of life of participants using specific questionnaires and record any side effects experienced during the treatment. The study is expected to continue until the end of 2026.

]]>